Dear Editor,
Recently, Axelrod and colleagues analyzed immune-related gene expression changes in breast cancer before and after neoadjuvant chemotherapy (Axelrod et al., 2020[1]). The authors analyzed 83 breast cancer tissue specimens, among them 44 triple negative carcinomas. An interesting result was that upregulation of immune-related genes was associated with better prognosis in the triple negative breast carcinomas (Axelrod et al., 2020[1]). Moreover, the authors studied PD-1Hi CD8+ peripheral T-cells for a cytolytic gene signature. Expression of cytotoxic genes in the peripheral blood was associated with worse prognosis, which may be explained by persistent micrometastatic disease that finally leads to recurrence (Axelrod et al., 2020[1]).
Numerous studies have analyzed the association of breast cancer with outcome, including the spontaneous course of disease and response to chemotherapy (Sparano et al., 2018[16]; Wang et al., 2018[19]; Finak et al., 2008[6]; van de Vijver et al., 2002[18]; Kwa et al., 2017[9]). High levels of T-cell and also B-cell/plasma cell associated genes were observed in breast carcinomas with relatively good prognosis (Schmidt et al., 2008[12], 2012[13], 2018[14]; Heimes et al., 2017[7]) but also in other tumor types (Edlund et al., 2019[5]; Lohr et al., 2013[10]). In contrast, antioxidative genes (Cadenas et al., 2010[2]) and genes associated with proliferation (Siggelkow et al., 2012[15]; Hellwig et al., 2016[8]; Cadenas et al., 2014[3]) and lipid (Cadenas et al., 2019[4]) as well as glycerophospholipid (Marchan et al., 2017[11]; Stewart et al., 2012[17]) metabolism are linked to worse prognosis. The current study of Axelrod et al. (2020[1]) is of high interest, because the authors systematically analyzed tumor tissue before and after chemotherapy and clearly demonstrated the prognostic role of genes associated with better response.
Conflict of interest
The author declares no conflict of interest.
References
- 1.Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer. Clin Cancer Res. 2020;epub ahead of print doi: 10.1158/1078-0432.CCR-19-3685. doi: 10.1158/1078-0432.CCR-19-3685. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res. 2010;12:R44. doi: 10.1186/bcr2599. doi: 10.1186/bcr2599. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014;13:3282–3291. doi: 10.4161/15384101.2014.954454. doi: 10.4161/15384101.2014.954454. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cadenas C, Vosbeck S, Edlund K, Grgas K, Madjar K, Hellwig B, et al. LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer. Int J Cancer. 2019;145:901–915. doi: 10.1002/ijc.32138. doi: 10.1002/ijc.32138. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Edlund K, Madjar K, Mattsson JSM, Djureinovic D, Lindskog C, Brunnström H, et al. Prognostic impact of tumor cell programmed death ligand 1 expression and immune cell infiltration in NSCLC. J Thorac Oncol. 2019;14:628–640. doi: 10.1016/j.jtho.2018.12.022. doi: 10.1016/j.jtho.2018.12.022. Available from: [DOI] [PubMed] [Google Scholar]
- 6.Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–527. doi: 10.1038/nm1764. doi: 10.1038/nm1764. Available from: [DOI] [PubMed] [Google Scholar]
- 7.Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Elger T, et al. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. Breast Cancer Res Treat. 2017;165:293–300. doi: 10.1007/s10549-017-4327-0. doi: 10.1007/s10549-017-4327-0. Available from: [DOI] [PubMed] [Google Scholar]
- 8.Hellwig B, Madjar K, Edlund K, Marchan R, Cadenas C, Heimes AS, et al. Epsin family member 3 and ribosome-related genes are associated with late metastasis in estrogen receptor-positive breast cancer and long-term survival in non-small cell lung cancer using a genome-wide identification and validation strategy. PLoS One. 2016;11:e0167585. doi: 10.1371/journal.pone.0167585. doi: 10.1371/journal.pone.0167585. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14:595–610. doi: 10.1038/nrclinonc.2017.74. doi: 10.1038/nrclinonc.2017.74. Available from: [DOI] [PubMed] [Google Scholar]
- 10.Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013;333:222–228. doi: 10.1016/j.canlet.2013.01.036. doi: 10.1016/j.canlet.2013.01.036. Available from: [DOI] [PubMed] [Google Scholar]
- 11.Marchan R, Büttner B, Lambert J, Edlund K, Glaeser I, Blaszkewicz M, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma. Cancer Res. 2017;77:4589–4601. doi: 10.1158/0008-5472.CAN-16-2065. doi: 10.1158/0008-5472.CAN-16-2065. Available from: [DOI] [PubMed] [Google Scholar]
- 12.Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68:5405–5413. doi: 10.1158/0008-5472.CAN-07-5206. doi: 10.1158/0008-5472.CAN-07-5206. Available from: [DOI] [PubMed] [Google Scholar]
- 13.Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012;18:2695–2703. doi: 10.1158/1078-0432.CCR-11-2210. doi: 10.1158/1078-0432.CCR-11-2210. Available from: [DOI] [PubMed] [Google Scholar]
- 14.Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, et al. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20(1):15. doi: 10.1186/s13058-018-0942-x. doi: 10.1186/s13058-018-0942-x. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, et al. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer. 2012;12:562. doi: 10.1186/1471-2407-12-562. doi: 10.1186/1471-2407-12-562. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–121. doi: 10.1056/NEJMoa1804710. doi: 10.1056/NEJMoa1804710. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, Ellis JK, et al. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A. 2012;109:8155–8160. doi: 10.1073/pnas.1117654109. doi: 10.1073/pnas.1117654109. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. doi: 10.1056/NEJMoa021967. doi: 10.1056/NEJMoa021967. Available from: [DOI] [PubMed] [Google Scholar]
- 19.Wang S, Beeghly-Fadiel A, Cai Q, Cai H, Guo X, Shi L, et al. Gene expression in triple-negative breast cancer in relation to survival. Breast Cancer Res Treat. 2018;171:199–207. doi: 10.1007/s10549-018-4816-9. doi: 10.1007/s10549-018-4816-9. Available from: [DOI] [PMC free article] [PubMed] [Google Scholar]